IFNA1 and acquired polycythemia vera: Evidence of significantly reduced seroconversion rates and lower antibody titres has also been documented in patients with MPNs after the first dose of the COVID‐19 vaccine, particularly in patients with ET and PV receiving hydroxycarbamide and patients receiving ruxolitinib, while responses in patients with ET and PV treated with pegylated IFN were relatively unimpaired.48